Claire Shannon‐Lowe

3.2k total citations · 2 hit papers
36 papers, 2.3k citations indexed

About

Claire Shannon‐Lowe is a scholar working on Oncology, Immunology and Epidemiology. According to data from OpenAlex, Claire Shannon‐Lowe has authored 36 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 16 papers in Immunology and 15 papers in Epidemiology. Recurrent topics in Claire Shannon‐Lowe's work include Viral-associated cancers and disorders (29 papers), Lymphoma Diagnosis and Treatment (14 papers) and Cytomegalovirus and herpesvirus research (13 papers). Claire Shannon‐Lowe is often cited by papers focused on Viral-associated cancers and disorders (29 papers), Lymphoma Diagnosis and Treatment (14 papers) and Cytomegalovirus and herpesvirus research (13 papers). Claire Shannon‐Lowe collaborates with scholars based in United Kingdom, Germany and United States. Claire Shannon‐Lowe's co-authors include Alan B. Rickinson, Martin Rowe, Andrew Bell, Henri‐Jacques Delecluse, Martina Vockerodt, Paul G. Murray, Regina Feederle, Maaike E. Ressing, Emmanuel J. H. J. Wiertz and Jianmin Zuo and has published in prestigious journals such as Nucleic Acids Research, Blood and The Journal of Immunology.

In The Last Decade

Claire Shannon‐Lowe

35 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Global Landscape of EBV-Associated Tumors

2019 305 citations Claire Shannon‐Lowe, Alan B. Rickinson profile →
Epstein–Barr virus-associated lymphomas

2017 293 citations Claire Shannon‐Lowe, Alan B. Rickinson et al. Philosophical Transactions of the Royal Society B Biological Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claire Shannon‐Lowe United Kingdom	27	1.7k	830	791	696	348	36	2.3k
Dagmar Pich Germany	21	1.5k 0.9×	563 0.7×	468 0.6×	935 1.3×	679 2.0×	29	2.3k
Heather M. Long United Kingdom	24	1.2k 0.7×	902 1.1×	553 0.7×	596 0.9×	173 0.5×	37	1.8k
Caroline Alfieri Canada	21	1.5k 0.9×	493 0.6×	675 0.9×	639 0.9×	190 0.5×	38	2.0k
Noémi Nagy Sweden	24	867 0.5×	787 0.9×	451 0.6×	285 0.4×	530 1.5×	71	1.8k
Dai Iwakiri Japan	19	955 0.6×	698 0.8×	309 0.4×	454 0.7×	578 1.7×	26	1.8k
Andreas Moosmann Germany	24	1.3k 0.8×	1.0k 1.2×	302 0.4×	830 1.2×	378 1.1×	54	2.1k
Wendy A. Thomas United Kingdom	17	1.5k 0.9×	1.1k 1.3×	677 0.9×	645 0.9×	199 0.6×	18	1.9k
Debbie Croom-Carter United Kingdom	24	2.5k 1.5×	1.1k 1.3×	1.4k 1.8×	674 1.0×	412 1.2×	26	3.2k
Ken‐Ichi Imadome Japan	22	859 0.5×	606 0.7×	409 0.5×	330 0.5×	188 0.5×	103	1.4k
Chris Dawson United Kingdom	14	891 0.5×	665 0.8×	264 0.3×	405 0.6×	579 1.7×	16	1.8k

Countries citing papers authored by Claire Shannon‐Lowe

Since Specialization

Citations

This map shows the geographic impact of Claire Shannon‐Lowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claire Shannon‐Lowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claire Shannon‐Lowe more than expected).

Fields of papers citing papers by Claire Shannon‐Lowe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claire Shannon‐Lowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claire Shannon‐Lowe. The network helps show where Claire Shannon‐Lowe may publish in the future.

Co-authorship network of co-authors of Claire Shannon‐Lowe

This figure shows the co-authorship network connecting the top 25 collaborators of Claire Shannon‐Lowe. A scholar is included among the top collaborators of Claire Shannon‐Lowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claire Shannon‐Lowe. Claire Shannon‐Lowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tarlinton, Rachael, Radu Tănăsescu, Claire Shannon‐Lowe, & Bruno Gran. (2024). Ocrelizumab B cell depletion has no effect on HERV RNA expression in PBMC in MS patients. Multiple Sclerosis and Related Disorders. 86. 105597–105597.

Maple, P.A.C., Alberto Ascherio, Jeffrey I. Cohen, et al.. (2022). The Potential for EBV Vaccines to Prevent Multiple Sclerosis. Frontiers in Neurology. 13. 887794–887794. 20 indexed citations

Wallaschek, Nina, Carmen Aguilar, Armin Wiegering, et al.. (2021). Ephrin receptor A2, the epithelial receptor for Epstein-Barr virus entry, is not available for efficient infection in human gastric organoids. PLoS Pathogens. 17(2). e1009210–e1009210. 24 indexed citations

Collins, Paul J., Christopher P. Fox, Hayden Pearce, et al.. (2020). Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. Blood. 137(2). 203–215. 26 indexed citations

Brocard, Michèle, et al.. (2018). Pumilio directs deadenylation-associated translational repression of the cyclin-dependent kinase 1 activator RGC-32. Nucleic Acids Research. 46(7). 3707–3725. 16 indexed citations

Shannon‐Lowe, Claire, Alan B. Rickinson, & Andrew Bell. (2017). Epstein–Barr virus-associated lymphomas. Philosophical Transactions of the Royal Society B Biological Sciences. 372(1732). 20160271–20160271. 293 indexed citations breakdown →

Brooks, Jill, Heather M. Long, Claire Shannon‐Lowe, et al.. (2016). Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination. PLoS Pathogens. 12(4). e1005549–e1005549. 37 indexed citations

Vento‐Tormo, Roser, Javier Rodríguez‐Ubreva, Lorena Di Lisio, et al.. (2014). NF-κB directly mediates epigenetic deregulation of common microRNAs in Epstein-Barr virus-mediated transformation of B-cells and in lymphomas. Nucleic Acids Research. 42(17). 11025–11039. 25 indexed citations

Vockerodt, Martina, Lee Fah Yap, Claire Shannon‐Lowe, et al.. (2014). The Epstein–Barr virus and the pathogenesis of lymphoma. The Journal of Pathology. 235(2). 312–322. 170 indexed citations

10.

Quinn, Laura L., Jianmin Zuo, Rachel J.M. Abbott, et al.. (2014). Cooperation between Epstein-Barr Virus Immune Evasion Proteins Spreads Protection from CD8+ T Cell Recognition across All Three Phases of the Lytic Cycle. PLoS Pathogens. 10(8). e1004322–e1004322. 44 indexed citations

11.

Shannon‐Lowe, Claire & Martin Rowe. (2014). Epstein Barr virus entry; kissing and conjugation. Current Opinion in Virology. 4. 78–84. 62 indexed citations

12.

Vockerodt, Martina, Fathima Zumla Cader, Claire Shannon‐Lowe, & Paul G. Murray. (2014). Epstein-Barr virus and the origin of Hodgkin lymphoma. Chinese Journal of Cancer. 33(12). 591–7. 26 indexed citations

13.

Hernando, Henar, Abul Bashar Mir Md. Khademul Islam, Javier Rodríguez‐Ubreva, et al.. (2013). Epstein–Barr virus-mediated transformation of B cells induces global chromatin changes independent to the acquisition of proliferation. Nucleic Acids Research. 42(1). 249–263. 29 indexed citations

14.

Heath, Emily, Sridhar Chaganti, Debbie Croom-Carter, et al.. (2012). Epstein-Barr Virus Infection of Naïve B Cells In Vitro Frequently Selects Clones with Mutated Immunoglobulin Genotypes: Implications for Virus Biology. PLoS Pathogens. 8(5). e1002697–e1002697. 56 indexed citations

15.

Fox, Christopher P., Tracey A. Haigh, Graham S. Taylor, et al.. (2010). A novel latent membrane 2 transcript expressed in Epstein-Barr virus–positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood. 116(19). 3695–3704. 63 indexed citations

16.

Zuo, Jianmin, Bryan D. Griffin, Claire Shannon‐Lowe, et al.. (2009). The Epstein-Barr Virus G-Protein-Coupled Receptor Contributes to Immune Evasion by Targeting MHC Class I Molecules for Degradation. PLoS Pathogens. 5(1). e1000255–e1000255. 143 indexed citations

17.

Croft, Nathan P., Claire Shannon‐Lowe, Andrew Bell, et al.. (2009). Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle. PLoS Pathogens. 5(6). e1000490–e1000490. 80 indexed citations

18.

Tierney, Rosemary J., et al.. (2007). Epstein-Barr Virus Exploits BSAP/Pax5 To Achieve the B-Cell Specificity of Its Growth-Transforming Program. Journal of Virology. 81(18). 10092–10100. 34 indexed citations

19.

Feederle, Regina, Bernhard Neuhierl, Helmut Bannert, et al.. (2007). Epstein‐Barr virus B95.8 produced in 293 cells shows marked tropism for differentiated primary epithelial cells and reveals interindividual variation in susceptibility to viral infection. International Journal of Cancer. 121(3). 588–594. 52 indexed citations

20.

Bar, Merav, Claire Shannon‐Lowe, & Adam P. Geballe. (2001). Differentiation of Human Cytomegalovirus Genotypes in Immunocompromised Patients on the Basis of UL4 Gene Polymorphisms. The Journal of Infectious Diseases. 183(2). 218–225. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact